Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Nasdaq: DBVT / Euronext: DBV) published its half-year report on the liquidity contract maintained with ODDO BHF, covering July 1, 2025 to December 31, 2025 and the contract inception on July 1, 2018.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT / Euronext: DBV) published its half-year report on the liquidity contract maintained with ODDO BHF, covering July 1, 2025 to December 31, 2025 and the contract inception on July 1, 2018.
As of December 31, 2025 the liquidity account held 74,580 shares and €527,891.63. At implementation on July 1, 2018 the account held 41,159 shares and €432,367.25. From Jul 1–Dec 31, 2025 the contract executed 1,658 buys and 1,867 sales, with traded volumes of 1,496,975 shares (€3,548,323.07) on purchases and 1,632,464 shares (€3,904,915.92) on sales.
Details
News Market Reaction – DBVT
On Jan 8, the first trading day after this news, DBVT closed 5.50% below the previous close.
Data tracked by StockTitan Argus for the Jan 8 session.
Key Figures
- Liquidity account shares (Dec 31, 2025)
- 74,580 shares
- Shares held under liquidity contract with ODDO BHF
- Liquidity account cash (Dec 31, 2025)
- €527,891.63
- Cash on liquidity account with ODDO BHF
- Initial liquidity shares (Jul 1, 2018)
- 41,159 shares
- Shares initially allocated to liquidity contract
- Initial liquidity cash (Jul 1, 2018)
- €432,367.25
- Cash initially allocated to liquidity contract
- Buy transactions
- 1,658
- Executed under liquidity contract from Jul 1 to Dec 31, 2025
- Sell transactions
- 1,867
- Executed under liquidity contract from Jul 1 to Dec 31, 2025
- Purchase volume
- 1,496,975 shares; €3,548,323.07
- Shares and euros bought under liquidity contract in H2 2025
- Sales volume
- 1,632,464 shares; €3,904,915.92
- Shares and euros sold under liquidity contract in H2 2025
Historical Context
-
Reported total shares and voting rights as of Dec 31, 2025.
-
Positive Phase 3 VITESSE topline results for VIASKIN Peanut patch.
-
Disclosed total shares and voting rights as of Nov 30, 2025.
-
Announced last patient visit completion in VITESSE Phase 3 trial.
-
Planned CEO fireside chat at Guggenheim healthcare conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
liquidity contract financial
isin financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
AMF Regulated Information
Châtillon, France, January 7, 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2025:
- 74,580 DBV Technologies shares,
€ 527,891.63 .
When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:
- 41,159 DBV Technologies shares,
€ 432,367.25 .
Over the period from July 1, 2025, to December 31, 2025, the following transactions were executed:
- 1,658 buy transactions,
- 1,867 sales transactions.
Over this same period, the volumes traded represented:
- 1,496,975 shares and
€ 3,548,323.07 on purchases, - 1,632,464 shares and
€ 3,904,915.92 on sales.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Viaskin is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.